A Study of YM178 in Patients With Symptomatic Overactive Bladder
- Registration Number
- NCT00527033
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo
- Detailed Description
To investigate the dose-response relationship of YM178 in terms of efficacy, safety and tolerability, and also the superiority of YM178 over placebo.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 842
Inclusion Criteria
- Patients over 20 years suffering from overactive bladder
Exclusion Criteria
- Pregnant and breastfeeding women
- Any clinically significant abnormal conditions which in the opinion of the investigator makes the patient unsuitable for the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 YM178 Oral 2 YM178 Oral 3 YM178 Oral 4 Placebo Oral
- Primary Outcome Measures
Name Time Method Overactive bladder symptoms 12 weeks
- Secondary Outcome Measures
Name Time Method Overactive bladder symptoms (QOL) 12 weeks